{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.10","upperLimit":"44.85","value":"39.3"},{"groupId":"OG001","lowerLimit":"26.78","upperLimit":"41.30","value":"31.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"description":"OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive.\n\nThe OS distribution was estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with advanced breast cancer with a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG000","title":"PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant"},{"description":"Subjects with advanced breast cancer with a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG001","title":"PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant"}],"paramType":"MEDIAN","populationDescription":"All subjects with a PIK3CA mutation (based on central testing of hotspot-mutations in tumor tissue) who were randomized to study treatment","reportingStatus":"POSTED","timeFrame":"Once approximately 178 deaths in the PIK3CA mutant cohort had been observed, up to 55.7 months","title":"Overall Survival (OS) in the PIK3CA Mutant Cohort","type":"SECONDARY","unitOfMeasure":"Months"}